119 related articles for article (PubMed ID: 18645033)
1. A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity.
Huebener N; Fest S; Strandsby A; Michalsky E; Preissner R; Zeng Y; Gaedicke G; Lode HN
Mol Cancer Ther; 2008 Jul; 7(7):2241-51. PubMed ID: 18645033
[TBL] [Abstract][Full Text] [Related]
2. DNA minigene vaccination for adjuvant neuroblastoma therapy.
Lode HN; Huebener N; Zeng Y; Fest S; Weixler S; Gaedicke G
Ann N Y Acad Sci; 2004 Dec; 1028():113-21. PubMed ID: 15650237
[TBL] [Abstract][Full Text] [Related]
3. Survivin minigene DNA vaccination is effective against neuroblastoma.
Fest S; Huebener N; Bleeke M; Durmus T; Stermann A; Woehler A; Baykan B; Zenclussen AC; Michalsky E; Jaeger IS; Preissner R; Hohn O; Weixler S; Gaedicke G; Lode HN
Int J Cancer; 2009 Jul; 125(1):104-14. PubMed ID: 19291796
[TBL] [Abstract][Full Text] [Related]
4. Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice.
Marx M; Zumpe M; Troschke-Meurer S; Shah D; Lode HN; Siebert N
PLoS One; 2018; 13(11):e0207320. PubMed ID: 30452438
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with minigenes encoding for novel 'self' antigens are effective in DNA-vaccination against neuroblastoma.
Huebener N; Lange B; Lemmel C; Rammensee HG; Strandsby A; Wenkel J; Jikai J; Zeng Y; Gaedicke G; Lode HN
Cancer Lett; 2003 Jul; 197(1-2):211-7. PubMed ID: 12880984
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma.
Lode HN; Pertl U; Xiang R; Gaedicke G; Reisfeld RA
Med Pediatr Oncol; 2000 Dec; 35(6):641-6. PubMed ID: 11107137
[TBL] [Abstract][Full Text] [Related]
7. Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice.
Stermann A; Huebener N; Seidel D; Fest S; Eschenburg G; Stauder M; Schramm A; Eggert A; Lode HN
Cancer Immunol Immunother; 2015 Oct; 64(10):1215-27. PubMed ID: 26076666
[TBL] [Abstract][Full Text] [Related]
8. Xenogeneic immunization with human tyrosine hydroxylase DNA vaccines suppresses growth of established neuroblastoma.
Huebener N; Fest S; Hilt K; Schramm A; Eggert A; Durmus T; Woehler A; Stermann A; Bleeke M; Baykan B; Weixler S; Gaedicke G; Lode HN
Mol Cancer Ther; 2009 Aug; 8(8):2392-401. PubMed ID: 19671753
[TBL] [Abstract][Full Text] [Related]
9. A minigene DNA vaccine encoding peptide epitopes derived from Galectin-1 has protective antitumoral effects in a model of neuroblastoma.
Liebscher L; Weißenborn C; Langwisch S; Gohlke BO; Preissner R; Rabinovich GA; Christiansen N; Christiansen H; Zenclussen AC; Fest S
Cancer Lett; 2021 Jul; 509():105-114. PubMed ID: 33848518
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma.
Pertl U; Wodrich H; Ruehlmann JM; Gillies SD; Lode HN; Reisfeld RA
Blood; 2003 Jan; 101(2):649-54. PubMed ID: 12393580
[TBL] [Abstract][Full Text] [Related]
11. A CD8+ T cell heptaepitope minigene vaccine induces protective immunity against Chlamydia pneumoniae.
Pinchuk I; Starcher BC; Livingston B; Tvninnereim A; Wu S; Appella E; Sidney J; Sette A; Wizel B
J Immunol; 2005 May; 174(9):5729-39. PubMed ID: 15843575
[TBL] [Abstract][Full Text] [Related]
12. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
13. A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis.
Lewēn S; Zhou H; Hu HD; Cheng T; Markowitz D; Reisfeld RA; Xiang R; Luo Y
Cancer Immunol Immunother; 2008 Apr; 57(4):507-15. PubMed ID: 17786443
[TBL] [Abstract][Full Text] [Related]
14. Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases.
Fest S; Huebener N; Weixler S; Bleeke M; Zeng Y; Strandsby A; Volkmer-Engert R; Landgraf C; Gaedicke G; Riemer AB; Michalsky E; Jaeger IS; Preissner R; Förster-Wald E; Jensen-Jarolim E; Lode HN
Cancer Res; 2006 Nov; 66(21):10567-75. PubMed ID: 17079481
[TBL] [Abstract][Full Text] [Related]
15. An autologous oral DNA vaccine protects against murine melanoma.
Xiang R; Lode HN; Chao TH; Ruehlmann JM; Dolman CS; Rodriguez F; Whitton JL; Overwijk WW; Restifo NP; Reisfeld RA
Proc Natl Acad Sci U S A; 2000 May; 97(10):5492-7. PubMed ID: 10779556
[TBL] [Abstract][Full Text] [Related]
16. Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer.
Williams BB; Wall M; Miao RY; Williams B; Bertoncello I; Kershaw MH; Mantamadiotis T; Haber M; Norris MD; Gautam A; Darcy PK; Ramsay RG
Cancer Immunol Immunother; 2008 Nov; 57(11):1635-45. PubMed ID: 18386000
[TBL] [Abstract][Full Text] [Related]
17. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes.
Ishioka GY; Fikes J; Hermanson G; Livingston B; Crimi C; Qin M; del Guercio MF; Oseroff C; Dahlberg C; Alexander J; Chesnut RW; Sette A
J Immunol; 1999 Apr; 162(7):3915-25. PubMed ID: 10201910
[TBL] [Abstract][Full Text] [Related]
18. Conjugation of new DNA vaccine with polyethylenimine induces cellular immune response and tumor regression in neuroblastoma mouse model.
Stegantseva MV; Shinkevich VA; Tumar EM; Meleshko AN
Exp Oncol; 2020 Jun; 42(2):120-125. PubMed ID: 32602294
[TBL] [Abstract][Full Text] [Related]
19. Quantitative and qualitative analyses of the immune responses induced by a multivalent minigene DNA vaccine.
An LL; Rodriguez F; Harkins S; Zhang J; Whitton JL
Vaccine; 2000 Apr; 18(20):2132-41. PubMed ID: 10715528
[TBL] [Abstract][Full Text] [Related]
20. Dendritic Cell Targeting Using a DNA Vaccine Induces Specific Antibodies and CD4
Zaneti AB; Yamamoto MM; Sulczewski FB; Almeida BDS; Souza HFS; Ferreira NS; Maeda DLNF; Sales NS; Rosa DS; Ferreira LCS; Boscardin SB
Front Immunol; 2019; 10():59. PubMed ID: 30761131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
